IL-24: A novel gene therapy candidate for immune system upregulation in Hodgkin’s lymphoma  by Manesh, Maryam Erfan et al.
Journal of Medical Hypotheses and Ideas (2015) 9, 61–66Available online at www.sciencedirect.com
Journal of Medical Hypotheses and Ideas
journal homepage: www.elsevier.com/locate/jmhiREGULAR ARTICLEIL-24: A novel gene therapy candidate
for immune system upregulation in Hodgkin’s
lymphomaAbbreviations: IL-24, cytokine interleukin-24; MDA-7, melanoma differentiation associated protein 7; HL, Hodgkin’s Lymphoma; N
nodular lymphocyte predominant Hodgkin’s Lymphoma; CHL, classical Hodgkin’s Lymphoma; HRS, Hodgkin and Reed–Sternber
Epstein–Barr virus; LMPs, latent membrane proteins; GMDSF, granulocyte-macrophage colony-stimulating factor; GADD, growth ar
DNA damage; TUNEL, transferase-mediated dUTP nick-end labeling method; IHC, immunohistochemistry; SCID mice, severe co
immunodeﬁcient mice; PBS, phosphate buffered saline.
* Corresponding author at: Department of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Tel.:
33440301, mobile: +98 912 1414281; fax: +98 24 33449553.
E-mail address: a46reza@zums.ac.ir (A. Esmaeilzadeh).
2251-7294 ª 2014 Tehran University of Medical Sciences. Published by Elsevier Ltd. All rights reserved.
URL: www.tums.ac.ir/english/
doi:http://dx.doi.org/10.1016/j.jmhi.2014.05.002Maryam Erfan Manesh a, Abdolreza Esmaeilzadeh b,c,*, Mehri Hajikhan Mirzaei da Young Researchers Club, Zanjan Branch, Islamic Azad University, Zanjan, Iran
b Department of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
c Cancer Gene Therapy Research Center, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
d Department of Medical Genome, Graduate School of Frontier Science, University of Tokyo, Tokyo, JapanReceived 11 June 2013; revised 1 December 2013; accepted 16 May 2014
Available online 24 May 2014KEYWORDS
Hodgkin Lymphoma;
IL-24;
Apoptosis;
Immune system
up-regulation;
Gene therapyAbstract Hodgkin’s Lymphoma (HL) as a prevalent hematolymphoid malignancy begins in cells
of immune system and is characterized by the speciﬁc histologic, clinical properties. Abnormality in
apoptosis has been recognized as a crucial pathway in its progression. Nowadays, 35–40% of
patients in stages III and IV show disease relapse or symptoms of refractory to ﬁrst-line chemother-
apy; therefore, novel treatment strategies are required. As apoptosis inducing is an important mech-
anism in cancer treatments, novel anticancer molecules to induce programmed cell death are
required. The authors present a novel therapeutic approach for HL, with regard to anti-tumoral
and immunomodulatory effects of the mda-7/IL-24. This gene, located in human chromosome
1q32-33, has shown tumor suppressor activity in various human malignant cells in, in vitro,
in vivo, and even in clinical trial studies. Our hypothesis was designed to evaluate anti- tumoralLPHL,
g; EBV,
rest and
mbined
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62 M.E. Manesh et al.effects of mda-7/IL-24 in SCID mice model using the adenovirus-based vector. mda-7/IL-24
interestingly has antiangiogenic, immunomodulatory, and bystander antitumoral activities.
mda-7/IL-24 can suppress anti-apoptotic Bcl-2 family proteins, and induces GADD family, Bak,
Bax, and other pro-apoptosis proteins. This hypothesis suggests that adenovirus vectors expressing
mda-7/IL-24 may help for effective immunotherapies of HL.
ª 2014 Tehran University of Medical Sciences. Published by Elsevier Ltd. All rights reserved.Introduction
Hodgkin’s lymphoma (HL) is considered as a hematolym-
phoid malignancy, primarily of B-cell lineage, with particular
histologic, immunologic, and clinical properties [1]. The
involvement of this lymphoid malignancy not only is restricted
to peripheral lymph nodes but also affects organs such as liver,
lung, and bone marrow [2–4]. Patients with HL are main sub-
jects of increased risk of secondary malignancies compared to
the healthy people [5]. Nowadays, the genetic abnormalities
involved in the pathogenesis of HL are still unknown; it has
been shown that chromosome aberrations, ampliﬁcations,
and deletions besides genetic aberration in NF-jB activation
are important defects in Hodgkin and Reed–Sternberg
(HRS) cells [6]. On the other hand, infection of HR-S cell pre-
cursors with the Epstein–Barr virus (EBV) and expression of
the viral latent membrane proteins (LMPs) 1 and 2a have an
important role in the pathogenesis of HL. Furthermore, in
HRS cells, activation of various signaling molecules such as
Notch1, several tyrosine kinase receptors, the PI3K and
MEK/ERK pathways, and the transcription factors NFjB,
STAT, AP-1, ATF-5, ATBF1, p21SNFT besides the potential
oncogenes, such as rhoC, L-myc, and PTP4A, have been impli-
cated in the etiology of HL [7,8]. As a whole, it has been
proved that HL cells are derived from a compartment of ger-
minal cancer B cells [9]. HL is a malignancy that involves
immune system and weakens the immune responses. HR-S
cells express several types of cytokines and chemokines for
interaction with T helper cells which lead to an abnormal
immune system like inhibition of Th1 responses using apopto-
sis induction of activated Th1 and CD8+ T cells. Cellular
inﬁltration also helps HR-S cell survival by providing an envi-
ronment that prevents cytotoxic T-cell immune responses. In
the HL microenvironment, secretion of CCL5, CCL17, and
CCL22 from HR-S cells attracts Th2 and Treg cells into the
microenvironment, as well as secretion of IL-5, IL-19, CCL5,
CCL28, and GM-CSF attracts eosinophils. Meanwhile,
CD4+ T cells ensure the growth of HR-S cells [3,9–12]. Treat-
ment of HL includes chemotherapy and radiation therapy;
unfortunately, the consequence of treatment just in fewer than
30% of patients is acceptable and patients with HL are subject
to a high risk of recurrence. In addition, unfavorable long-
lasting outcomes of treatment and the immediate toxicity for
the other cells could exclude their application [13–15]. Conse-
quently, the side effects of these methods made us to develop
a novel treatment approach for HL. In order to gain this goal,
we focused on gene therapy, involving selective replacement of
tumor suppressor genes that promote tumor growth suppres-
sion or direct destruction, by induction of programmed cell
death represent treatment and immune system upregulationapproaches [16,17]. This aspiration is achieved using some
cytokines such as mda-7/IL-24 gene which is located in the
human chromosome 1q32-33. Based on sequence homology,
chromosomal localization, and its functional properties, the
mda-7 gene is now categorized as a member of the IL-10 family
of cytokines and named IL-24 [18]. IL-24 signals in physiologic
condition, triggers via binding to heterodimeric receptors, IL/
20R1/R2 and IL-22R1/IL20R2 with R1 and R2 subunits
[19–22]. The IL-24 receptor is expressed on the cells of skin,
lung, and reproductive tissues which are non-hematopoietic
[23]. It is also expressed on neutrophils, CD4+ T cells,
CD8+ T cells [20], liver cancer cells [24], keratinocytes [22],
pancreatic myoﬁbroblasts [25], and epithelial and stromal cells
of various tissues [26]. IL-24 plays anti-tumoral roles in a
broad spectrum of human cancer cells [27–29]. Expression of
IL-24 was successfully applied in treatment of breast cancer
cells, induced selective apoptosis, and inhibited breast tumoral
cell growth in nude mice [30]. Several independent studies have
shown that a majority of human cancer-derived cell lines,
including melanoma, prostate, cervical, lung, pancreatic, colo-
rectal, glioma, breast, ovarian, hepatocarcinoma, and myeloid
leukemia, underwent apoptosis when exposed to IL-24 [18].
Nonetheless, it does not affect normal human cell growth
and viability [31,32]. On the other hand, it is well documented
that interleukins play a fundamental role in stimulating or sup-
pressing the immune system. In the case of immune system
activation function of IL-24, the receptors couple with the
IL-24 to induce a biologic response. Promoting immune acti-
vation occurs by antigen and tumor-speciﬁc T-cell response,
following increased IFN-c production and cytolytic activity,
induction of pro-Th1 cytokine secretion as IFN-c, IL-6,
TNF-a, IL1b, IL-12, and GM-CSF in PBMCs, increasing
cytokine circulation such as IL-6, IL-10, and TNF-a, and
meaningful enhancement in CD3+ and CD8+ T cells. Upregu-
lation of IFN-c results in IL-22R1 expression in keratinocytes
and IL-22R1/IL-20R2 complex improves the innate immunity
of tissues. These effects are mediated by STAT/JNK depen-
dent signaling pathway. It has been also reported that IL-24
activates PKR which is responsible for cell growth and differ-
entiation, tumor suppression, and immune activation. Interest-
ingly, IL-24 prevents differentiation of germinal center B cells
into mature plasma cells by downregulation of IRF4, Blimp1,
and Bcl6 transcription factors [33,34].
IL-24 signaling pathway
At normal physiological levels, mda-7/IL-24 protein binds to
IL/20R1/R2 and IL-22R1/IL20R2 heterodimer receptors and
activates STAT-3 and STAT-1 transcription factors that
control growth and differentiation in response to ligand bind-
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mda-7/IL-24, this cytokine can inhibit cell growth and induce
apoptosis in tumor cells via multiple mechanisms including
disturbance in signaling pathways as p38 mitogen-activated
protein kinase and c-Jun NH2-terminal kinase, antiangiogenic
actions, immune modulation, bystander antitumor activity,
autocrine regulation, induction of oxidative damage, and
modulation of the expression of pro- and antiapoptotic Bcl-2
family members. Moreover, mda-7/IL-24 triggers endoplasmic
reticulum stress (ER stress) in transformed cells. mda-7/IL-24
binding to the ER resident chaperone protein GRP78/BiP is
responsible for initiating ER stress. This binding will be
followed by induction of DNA damage-inducible genes such
as GADD153, GADD45a, and GADD34, then calcium
release into the cytosol, PKR-like ER kinase will be activated.
This process will lead to eIF2a phosphorylation, and protein
translation inhibition [35–37]. Additional studies demon-
strated that IL-24 induces suppression of cell growth so that
G2 phase cell-cycle arrest in cancer cells is induced through
inhibition of Chk1 and Chk2, which are activated in DNA
damaging and inhibition of the Cdc25C pathway. IL-24
inhibits from phosphorylation of the Cdc25C on Serin-216
which had been previously introduced as the G2 checkpoint
regulator [38].Hypothesis
In this hypothesis, a strategy for immune gene therapy is sug-
gested for HL treatment. IL-24 can be utilized in HL treatment
by apoptosis induction and cell growth arrest besides immune
system regulation. The injection of IL-24 gene into the animal
model via adenoviruses for their high transfection efﬁcacy [39],
carrying this gene, can be a proper alternative treatment that
causes IL-24 overexpression and results in apoptosis of cancer-
ous cells and immune response upregulation.
Evaluation of hypothesis
To test the hypothesis, the authors have proposed the follow-
ing experiment:
(1) A total of 40 female severe combined immunodeﬁcient
(SCID) mice (at the age of 4–8 weeks) are selected
[40,41]. The ﬁrst group (n= 10) is the control group,
which does not receive any injection. The remaining
mice are divided into three of 10 animals per group
[29,42], including the following:(a) The mice are available for an L540Cy cell line
inoculation subcutaneously (s.c.) in order to ind-
uce a tumor without IL-24 transfection [43,44].
(b) The next group has mice with HL, receiving IL-24
gene via Ad.5/3 recombinant adenovirus [45].
(c) The last group contains mice receiving adenovirus
without the IL-24 gene.(2) The L540Cy cell line is a subline of L540 [40] and is
grown in RPMI-1640 medium containing 10% heat-
inactivated fetal bovine serum, 50 U/ml penicillin,50 ng/ml streptomycin, and 4 mM L-glutamine. The
cells are maintained in a 5% CO2 humidiﬁed atmosphere
at 37  [46].
(3) Exponentially growing cells (2.5 · 107) re-suspended in
200 ll of phosphate-buffered saline (PBS) are injected
into the right ﬂank (s.c.) of mice with a 26-gauge needle
to induce HL [47].
(4) In order to evaluate IL-24 effects on the cancerous cell
growth, pathologic aspects of tumor cells with immuno-
chemistry methods such as Western blotting and IHC
analysis in both the control group and the group treated
with IL-24 gene are performed [39].
(5) IL-24 is fused and introduced into an adenovirus vector
system [39].
(6) Real-time PCR is applied to measure levels of IL-24 in
cells in the four groups.
(7) Apoptosis assay is performed using the transferase-
mediated dUTP nick-end labeling method (TUNEL).
The tumor cells are labeled by ﬂuorescence and then
observed under a ﬂuorescent microscope [39,48].
(8) Tumor necrosis factor-a (TNF-a), interferon gamma
(IFN-c), and transforming growth factor b (TGF-b)
production are measured using enzyme-linked immuno-
sorbent assay (ELISA) [49].
Discussion and conclusion
Malignant cells can grow in the presence of growth factors
provided by the microenvironment, besides the inhibition of
antitumor immune responses. There is an important interac-
tion between these two components mediated by cytokines
and chemokines. The mechanism that tumoral cells use to
escape from immune response is speciﬁc polarized immune
cells towards a Th2 response. HRS cells stimulate ﬁbroblasts
through various factors such as TNFa, TGF-b, and ﬁbroblast
growth factors, and the activation of ﬁbroblasts could lead to
enhance eotaxin and CCL5 production, and attraction of
eosinophils and Tregs into the lymphoma. HRS cells also
regulate their microenvironment to evade from an attack by
cytotoxic T cells or natural killer cells and they can play a sig-
niﬁcant role in inhibition of Th1 responses. Overall conse-
quence of HL is reduction in responses of immune system.
As the post-treatment recurrence rate and the metastasis rate
in patients with HL remain high and up to 30% and 10% of
patients will have recurrence and die of HL in advanced and
early disease, respectively [50]. In this hypothesis, a new treat-
ment is suggested. As HL is an ideal target for immunother-
apy [13], the authors have introduced the IL-24 gene
overexpression via adenovirus vector system [39] into HL
SCID mice model. Recent studies have shown that mda-7/
IL-24 could selectively induce apoptosis in many various
tumoral cells such as melanoma, prostate, cervical, lung, pan-
creatic, colorectal, glioma, breast, ovarian, hepatocarcinoma,
and myeloid leukemia [18,51]. Surprisingly, a replication-
defective adenovirus can carry IL-24 with high efﬁcacy and
safety during phase I and phase II clinical trials [52], whereas
this cytokine does not have inﬂuence on normal cells [31,32].
Surprisingly, the apoptosis-inducing ability of IL-24 is not
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
IL-24 has been introduced with anticancerous prop-
erty on tumor cells which has no harmful effect on
normal cells. IL-24 has an important role in anti-
angiogenic mechanism, bystander antitumor activity,
autocrine regulation, immune response modulation,
bystander antitumor activity, autocrine regulation,
suppression of anti-apoptotic Bcl-2 family proteins,
and induction of GADD family, Bak, Bax, that leads
to apoptosis induction. Many studies show cytotoxic
effects of IL-24 in many types of cancer cell lines.
So it is suggested that IL-24 can induce apoptosis in
HL tumoral cells and activate immune system.
Third Question: Among numerous available studies,
what special further study is proposed for testing the
idea?
This hypothesis is evaluated by inducing HL in the
SCID mouse model using direct injection of tumor
cell lines into mice. Then, effect of the treatment with
IL-24 via an adenovirus vector in mouse tumor cells is
investigated using immune assays and apoptosis
assays.
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synergistic anti-tumor effects of IL-24, including apoptosis
inducing, anti-angiogenic and immune-stimulating effects
have been on focus. Zheng et al. found that adenovirus trans-
duction of IL-24 leads to G2/M cell-cycle arrest [52]. At nor-
mal physiological levels, mda-7/IL-24 protein binds to IL/
20R1/R2 and IL-22R1/IL20R2 heterodimer receptors and
activates STAT-3 and STAT-1 transcription factors that con-
trol growth and differentiation in response to ligand binding
[32]. IL-24 also has impressive immune stimulatory activity
after binding to its receptors. It activates IL-6, tumor necrosis
factor-a (TNF-a), and interferon production and has been
shown to signiﬁcantly downregulate transforming growth
factor b (TGF-b [16,53,54]). Upregulation of IFN-c leads to
improvement of innate immunity. IL-24 protein ultimately is
involved in regulation of inﬂammatory and immune responses
[55]. This mechanism is really critical in suppression of
tumoral cells in HL. Meanwhile, enforced expression of
mRNA and protein of mda-7/IL-24 inhibits cell growth and
induces apoptosis in tumor cells via multiple mechanisms
including disturbance in signaling pathways as p38 mitogen-
activated protein kinase and c-Jun NH2-terminal kinase, anti-
angiogenic actions, immune modulation, bystander antitumor
activity, autocrine regulation, overexpression of pro-apoptotic
and downregulating anti-apoptotic proteins. In addition, mda-
7/IL-24 can bind to GRP78/BiP, and starts ER stress, fol-
lowed by the induction of GADD153, GADD45a, and
GADD34, calcium releasing into the cytosol, PKR-like ER
kinase activation, eIF2a phosphorylation, and inhibition of
anti-apoptotic proteins translation [18,36,37]. Furthermore,
mda-7 has the ability of decreasing drug resistance in some
malignant cell lines [56].
Consequently, these pathways have the potential to be
utilized in induction of apoptosis in HL. This hypothesis
proposes HL treatment using adenovirus as a vector to
transmit the IL-24 gene into HL cell line in SCID mice.
Ad.IL-24 selectively suppresses growth of cancerous cells
and induces apoptosis, but it had no impact on the normal
cells [16]. In terms of immunological approaches, IL-24
can strengthen the immune system which would recompense
immunity weakness caused by pathogenesis of HL. Accord-
ingly, signaling pathway induced by IL-24 may operate as a
novel remedial issue for HL treatment. Designing a clinical
study to examine its impact on HL in humans can be the
next suggestion.Overview Box
First Question: What do we already know about the
subject?
From a public health perspective, Hodgkin’s lym-
phoma is one of the most prevalent malignancies
among other lymphomas with considerable reduction
in immune system performance. Chemotherapy and
radiation therapy are present remedial approaches
which are not quite helpful.Conﬂicts of interest
The authors have no conﬂicts of interest to declare.Acknowledgment
We take this opportunity to represent our profound apprecia-
tion to Dr. A. R. Esmaeilzadeh for supervising and inspiring us
greatly to accomplish this hypothesis.
References
[1] Grimm S, Chamberlain M. Hodgkin’s lymphoma: a review of
neurologic complications. Adv. Hematol. 2011;2011:1–7.
[2] Mirijello A, Addolorato G, Landolﬁ R. Hodgkin’s lymphoma
presenting as chest pain. IJCM 2013;4:32–4.
[3] Kuppers R, Engert A, Hansmann M. Hodgkin lymphoma. J.
Clin. Invest. 2012;122(10):3439–47.
[4] Gibcus JH, Tan LP, Harms G, Schakel RN, Jong D, Blokzijl T,
et al. Hodgkin lymphoma cell lines are characterized by a
speciﬁc mirna expression proﬁle. Neoplasia 2009;11:167–76.
[5] Gotti M, Fiaccadori V, Bono E, Landini B, Varettoni M,
Arcaini L, et al. Therapy-related late adverse events in
Hodgkin’s lymphoma. Lymphoma 2013;2013:1–7.
[6] Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer
K, Huntsman D, et al. Sub-megabase resolution tiling (SMRT)
IL-24: A novel gene therapy candidate for immune system upregulation in Hodgkin’s lymphoma 65array-based comparative genomic hybridization proﬁling reveals
novel gains and losses of chromosomal regions in Hodgkin
lymphoma and anaplastic large cell lymphoma cell lines. Mol.
Cancer 2008;7(2):1–13.
[7] Brauninger A, Schmitz R, Bechte D, Renne C, Hansmann ML,
Kuppers R. Molecular biology of Hodgkin’s and Reed/
Sternberg cells in Hodgkin’s lymphoma. Int. J. Cancer
2006;118:1853–61.
[8] Schwering I, Brauninger A, Distler V, Jesdinsky J, Diehl V,
HansmannML, et al. Proﬁling of Hodgkin’s lymphoma cell line
L1236 and germinal center B cells: identiﬁcation of Hodgkin’s
lymphoma–speciﬁc genes. Mol. Med. 2003;9:85–95.
[9] Kawakami MM, Kawakami KK, Kioi MM, Leland PP, Puri
RK. Hodgkin lymphoma therapy with interleukin-4 receptor-
directed cytotoxin in an inﬁltrating animal model. Blood
2005;105(9):3707–13.
[10] Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis
of Hodgkin’s lymphoma: increasing evidence of the importance
of the microenvironment. JCO 2011;29(14):1812–26.
[11] Poppema S. Immunobiology and pathophysiology of Hodgkin
lymphomas. Hematology 2005:231–8.
[12] Kuppers R. Molecular biology of Hodgkin lymphoma.
Hematology 2009:491–6.
[13] Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Othe T,
et al. Recombinant Anti-CD25 immunotoxin RFT5(scFv)-
ETA9 demonstrated successful elimination of disseminated
human Hodgkin lymphoma in SCID mice. Int. J. Cancer
2000;86:718–24.
[14] Armitage JO. Early-stage Hodgkin’s lymphoma. N. Engl. J.
Med. 2010;363:653–62.
[15] Radford J. Treatment for early-stage Hodgkin lymphoma: has
radiotherapy had its day? J. Clin. Oncol. 2012;30(31), pp. 3785–
83.
[16] Fisher PB. Is mda-7/IL-24 a magic bullet for cancer? Cancer
Res. 2005;65(22):10128–38.
[17] Sahoo A, Im SH. Molecular mechanisms governing IL-24 gene
expression. Immun. Netw. 2012;12(1):1–7.
[18] Dash R, Bhutia SK, Azab B, Su Z, Quinn BA, Kegelmen TP,
et al. Mda-7/IL-24: a unique member of the IL-10 gene family
promoting cancer-targeted toxicity. Cytokine Growth Factor
Rev. 2010;21:381–91.
[19] Patani N, Douglas-Jones A, Mansel R, Jiang W, Mokbel K.
Tumour suppressor function of MDA-7/IL-24 in human breast
cancer. Cancer Cell Int. 2010;10(29):1–9.
[20] Amirzada MI, Jin J. Therapeutic applications of interleukin 24
(IL24): a review. Trop. J. Pharm. Res. 2012;11(6):1023–7.
[21] Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR,
Walter MR. Structural basis for receptor sharing and activation
by interleukin-20 receptor-2 (IL-20R2) binding cytokines. PNAS
2012;7:1–6.
[22] Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24
(MDA-7/MOB-5) signals through two heterodimeric receptors,
IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J. Biol. Chem.
2002;277(9):7341–7.
[23] WangM, Liang P. Interleukin-24 and its receptors. Immunology
2005;114:166–70.
[24] Zhu H, Yang ZB. Expression pattern of mda-7/IL-24 receptors
in liver cancer cell lines. Hepatobiliary Pancreat. Dis. Int.
2009;8(4):402–6.
[25] Imaeda H, Nishida A, Inatomi O, Fujiyama Y, Andoh A.
Expression of interleukin- 24 and its receptor in human
pancreatic myoﬁbroblasts. Int. J. Mol. Med. 2011;28:993–9.
[26] Nagalakshmi ML, Murphy E, McClanahan T, Malefyt RW.
Expression patterns of IL-10 ligand and receptor gene families
provide leads for biological characterization.
Immunopharmacology 2004;4(5):577–92.
[27] Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV,
Dent P, et al. MDA-7/IL-24: novel cancer growth suppressingand apoptosis including cytokine. Cytokine Growth Factor Rev.
2003;14:35–51.
[28] Jia J, Li S, Gong W, Ding J, Fang C, Quan Z. Mda-7/IL-24
induces apoptosis in human GBC-SD gallbladder carcinoma
cells mitochondrial apoptotic pathway. Oncol. Rep.
2011;25:195–201.
[29] Hajikhanmirzaei M, Esmaeilzadeh A. Overexpression of MDA-
7/IL-24 as an anticancer cytokine in gene therapy of thyroid
carcinoma. JMHI 2014;8(1):7–13.
[30] Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P,
et al. Unique aspects of mda-7/IL-24 antitumor bystander
activity: establishing a role for secretion of MDA-7/IL-24
protein by normal cells. Oncogene 2005;24:7552–66.
[31] Sarkar D, Su Z, Lebedeva IV, Sauane M, Gopalkrishnan RV,
Valerie K, et al. Mda-7 (IL-24) mediates selective apoptosis in
human melanoma cells by inducing the coordinate
overexpression of the GADD family of genes by means of p38
MAPK. PNAS 2002;99(15):10054–9.
[32] Gopalkrishnan RV, Sauane M, Fisher PB. Cytokine and tumor
cell apoptosis inducing activity of mda-7/IL-24. Int.
Immunopharmacol. 2004;4:635–47.
[33] Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB,
Leitner WW, et al. MDA-7/IL-24 is a unique cytokine–tumor
suppressor in the IL-10 family. Int. Immunopharmacol.
2004;4:649–67.
[34] Maarof G, Bouchet-Delbos L, Gary-Gouy H, Durand-Gasselin
I, Krzysiek R, Dalloul A. Interleukin-24 inhibits the plasma cell
differentiation program in human germinal center B cells. Blood
2010;115:1718–26.
[35] Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L,
Randolph A, et al. Induction of cancer-speciﬁc apoptosis BiP/
GRP78 is an intracellular target for MDA-7/IL-24. Cancer Res.
2006;66(16):8182–91.
[36] Park MA, Yacoub A, Sarkar D, Emdad L, Rahmani M, Spiegel
S, et al. PERK-dependent regulation of MDA-7/IL-24-induced
autophagy in primary human glioma cells. Autophagy
2008;4(4):513–5.
[37] Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar
D, et al. Melanoma differentiation associated gene-7/
Interleukin-24 potently induces apoptosis in human myeloid
leukemia cells through a process regulated by endoplasmic
reticulum stress. Mol. Pharmacol. 2010;78(6):1096–104.
[38] Saito Y, Miyahara R, Gopalan B, Litvak A, Inoue S,
Shanker M, et al. Selective induction of cell cycle arrest and
apoptosis in human prostate cancer cells through adenoviral
transfer of mda-7/IL-24 gene. Cancer Gene Ther.
2005;12:238–47.
[39] Li J, Shi L, Zhang X, Kang X, Wen Y, Qian H, et al.
Recombinant adenovirus IL-24-Bax promotes apoptosis of
hepatocellular carcinoma cells in vitro and in vivo. Cancer
Gene Ther. 2010;17:771–9.
[40] Kapp U, Wolf J, Kalle C, Tawadros S, Rottgen A, Engert A,
et al. Preliminary report: growth of Hodgkin’s lymphoma
derived cells in immune compromised mice. Ann. Oncol.
1992;3(4):21–3.
[41] Kapp U, Wolf J, Hummel M, Pawlita M, Kalle C, Dallenbach
F, et al. Combined immunodeﬁcient mice Hodgkin’s
lymphoma-derived tissue serially transplanted into severe.
Blood 1993;82(4):1247–56.
[42] Mazaheri T, Esmaeilzadeh AR, Mirzaei HKHM. Introducing
the immunomodulatory effects of mesenchymal stem cells in
an experimental model of Behcet’s disease. JMHI
2012;6(1):23–7.
[43] Kung Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J,
Cerveny CG, Yu C, et al. Lysosomal trafﬁcking and cysteine
protease metabolism confer target-speciﬁc cytotoxicity by
peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem.
2006;281(15):10540–7.
66 M.E. Manesh et al.[44] Okeley NM, Miyamoto JB, Zhang X. Antibody-drug conjugate
intracellular activation of SGN-35, a potent anti-CD30. Clin.
Cancer Res. 2010;16(3):888–97.
[45] Dash R, Dmitriev I, Su Z, Bhutia SK, Azab B, Vozhilla N, et al.
Enhanced delivery of mda-7/IL-24 using a serotype chimeric
adenovirus (Ad.5/3) improves therapeutic efﬁcacy in low CAR
prostate cancer cells. Cancer Gen. Ther. 2010;17:447–56.
[46] Kapp U, Dux A, Schell-Frederick E, Banik N, Hummel M,
Miicke S, et al. Disseminated growth of Hodgkin’s-derived cell
lines L540 and L540cy in immune-deﬁcient SCID mice. Ann.
Oncol. 1994;5:121–6.
[47] Kapp U, Dux A, Schell-Frederick E, Banik N, Hummel M,
Miicke S, et al. Growth of Hodgkin cell lines in severely
combined immunodeﬁcient mice. Int. J. Cancer 1992;52:
887–91.
[48] Piri Z, Esmaeilzadeh A, Hajikhanmirzaei M. Interleukin-25 as a
candidate gene in immunogene therapy of pancreatic cancer.
JMHI 2012;6:75–9.
[49] Li C, Sanni LA, Omer F, Riley E, Langhorne J. Pathology of
Plasmodium chabaudi chabaudi infection and mortality in
interleukin-10-deﬁcient mice are ameliorated by anti-tumor
necrosis factor alpha and exacerbated by anti-transforming
growth factor-a antibodies. Infect. Immunol. 2003;71(9):
4850–6.[50] Cruz-Merino L, Lejeune M, Fernandez EN, Carrasco FH,
Lopez AG, Vacas AI, et al. Role of immune escape mechanisms
in Hodgkin’s lymphoma development and progression: a whole
new world with therapeutic implications. Clin. Dev. Immunol.
2012:1–24.
[51] Huo W, Li ZM, Zhu XM, Bao YM, An LJ. MDA-7/IL-24
suppresses tumor adhesion and invasive potential in hepatocellular
carcinoma cell lines. Oncol. Rep. 2013;30(2):986–92.
[52] Zhu W, Wei L, Zhang H, Chen J, Qin X. Oncolytic adenovirus
armed with IL-24 Inhibits the growth of breast cancer in vitro
and in vivo. J. Exp. Clin. Cancer Res. 2012;31(51).
[53] Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm
EA. Soluble human MDA-7/IL-24: characterization of the
molecular form(s) inhibiting tumor growth and stimulating
monocytes. J. Interferon Cytokine Res. 2006;26(12):877–86.
[54] Zhang BF, Liu JJ, Pei DS, Yang ZX, Di JH, Chen FF, et al.
Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24
mutant, via targeting the integrin receptor of tumor cells. Cancer
Biother. Radiopharm. 2011;26(5):647–55.
[55] Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine
induction of interleukin-24 in human peripheral blood
mononuclear cells. J. Leukoc. Biol. 2005;78:745–52.
[56] Wang Q, Zhu Y, Yang P. Is Mda-7/IL-24 a potential target and
biomarker for enhancing drug sensitivity in human glioma U87
cell line? Anat. Rec. 2013;296(8):1154–60.
